Skip to content
Biodatica
Start free

Sichuan Baili Pharmaceutical Co., Ltd.

Guangzhou, Guangdong

OncologyantibodyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

2mo agoTrial registeredMay 6, 2026Source filing (opens the source filing in a new tab)

Momentum

91no change

Momentum 91 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Aug 7, 2024

    Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

    ClinicalTrials.gov · NCT06500026 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jul 18, 2024

    Solid Tumor · RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT06475131 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jun 25, 2024

    Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor · RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

    ClinicalTrials.gov · NCT06475300 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    May 22, 2024

    Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)

    ClinicalTrials.gov · NCT06382116 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Dec 4, 2023

    Nasopharyngeal Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

    ClinicalTrials.gov · NCT06118333 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Apr 17, 2020

    Locally Advanced or Metastatic Epithelial Tumor · ACTIVE_NOT_RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

    ClinicalTrials.gov · NCT04603287 (opens the source filing in a new tab)

  7. Grant

    R01 · $581k · non-dilutive

    Aug 1, 2007

    UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LI I · NIDCD · award ends Aug 31, 2029 · Contribution of striatum to central auditory processing

    NIH RePORTER · NIH RePORTER 11131250 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources